Granted Patent B2

US 12,583,920 · App. 17/712,167 · Granted Mar 24, 2026

Inventors: Dudley K. Strickland (Brookeville, MD); Joanna Cooper (Baltimore, MD); Selen M. Catania (Brookeville, MD); Mary M. Migliorini (Derwood, MD); Brian Hampton (Gaithersburg, MD); Bradley T. Hyman (Madison, NH); Aurelien Lathuiliere (Cambridge, MA)

Assignees: UNIVERSITY OF MARYLAND, BALTIMORE; THE GENERAL HOSPITAL CORPORATION

C07K16/28A61P25/28A61P35/00C07H21/02C07K14/705C12N15/1138A61K38/00C07K2317/76C12N2310/14C12N2320/32C12N2320/51

Abstract

Claims (9)

1 . A method of reducing tau internalization and/or trafficking in neuronal cells to treat Alzheimer's disease in a subject, comprising contacting the neuronal cells of the subject with i) an effective amount of a SorLA antagonist; or ii) an effective amount of an LRP1 antagonist and a SorLA antagonist, wherein the SorLA antagonist is an siRNA and the LRP1 antagonist is receptor associated protein (RAP) or a fragment thereof comprising the D3 domain.

2 . The method of claim 1 , wherein the LRP1 antagonist is receptor associated protein (RAP).

3 . The method of claim 1 , wherein the effective amount of a SorLA antagonist or the effective amount of an LRP1 antagonist and the SorLA antagonist are administered to the subject intrathecally and/or intraventricularly.

4 . The method of claim 1 , wherein the siRNA targets a portion of SorLA mRNA corresponding to SEQ ID NO:2.

5 . The method of claim 1 , wherein the siRNA has a target sequence comprising any of SEQ ID NOS:5-8.

6 . The method of claim 1 , wherein the siRNA has a target sequence comprising SEQ ID NO:5.

7 . The method of claim 1 , wherein the siRNA has a target sequence comprising SEQ ID NO:6.

8 . The method of claim 1 , wherein the siRNA has a target sequence comprising SEQ ID NO:7.

9 . The method of claim 1 , wherein the siRNA has a target sequence comprising SEQ ID NO:8.

Assignments (2)

Continuity (2)

References Cited (9)